Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Innovation Pharmaceuticals Inc (IPIX) Message Board

FTC is at least doing something about acammers:

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 72447
(Total Views: 285)
Posted On: 05/06/2018 3:58:44 PM
Avatar
Posted By: someconcerns
Re: someconcerns #45268
FTC is at least doing something about acammers:

Quote:
FTC Settlement Turns Down the Volume on Deceptive Sound Amplifier Ads
Defendants could not back up efficacy claims made for their MSA 30X device

For Release
May 2, 2018

Tags:

Bureau of Consumer Protection Consumer Protection Advertising and Marketing Health Claims

A set of Florida-based entities and their owner are settling Federal Trade Commission charges that advertisements for their MSA 30X sound amplifier deceptively claimed the device is “independently tested to help you hear up to 30 times better.” Under a court order settling the FTC’s complaint, the defendants will be barred from making similar unsupported claims in the future, and from representing their claims are based on scientific evidence if they are not.

According to the FTC’s complaint, corporate defendants Global Concepts Limited, Inc., which did business under the name Global TV Concepts, Ltd., GCL Product Holdings, LLC, and MSA 30X LLC deceptively advertised MSA 30X to consumers nationwide, in violation of the FTC Act. Individual defendant Laurie Braden is the principal owner and officer of the corporate defendants, which are based in Deerfield Beach, Florida.

The FTC alleges that since at least 2012, Braden and the corporate defendants advertised and sold MSA 30X, a small, rechargeable electronic wearable sound amplifier product. Through 2017, the defendants sold nearly three million of the devices, including through retailers such as CVS, Walgreens, and Walmart, generating total sales of $47.2 million. The defendants also advertised the amplifiers directly to consumers via TV ads, with a toll-free number consumers could call to place an order, and several company-owned websites, including a Spanish-language site.

The TV ads featured older consumers frustrated with not being able to hear in settings such as a restaurant or at home watching television. Their hearing difficulties are resolved, however, upon using the MSA 30X. For example, in one commercial, a wife complains about how loud her husband has the television turned up. With the aid of the MSA 30X, the husband is able to watch television at a more moderate volume while still claiming “to hear everything clearly.” The TV ads also claimed the device was “independently tested” to help consumers “hear up to 30 times better.” The websites contained similar claims.

According to the FTC, however, the defendants did not possess adequate evidence that the MSA 30X actually helped consumers hear better in the advertised circumstances. Likewise, the FTC alleges defendants did not possess independent tests showing the MSA 30X helped consumers hear thirty times better.

The proposed court order settling the FTC’s charges first addresses the allegations that the defendants’ ads included false or unsubstantiated claims, including that the MSA 30X: 1) allows users who have trouble hearing to clearly hear when watching TV at a moderate volume; 2) helps users hear up to 30 time better; and 3) lets users who have trouble hearing hear clearly, without missing a word, in crowded places like movie theaters or restaurants. Accordingly, the order bars the defendants from making such claims unless they are supported by competent and reliable scientific evidence.

Next, the order prohibits the defendants from making any efficacy claims about any device, not just the MSA 30X, unless the claim is not misleading, and at the time it’s made, the defendants have the scientific evidence necessary to support it. The order also prohibits the defendants from misrepresenting test results or studies, and requires them to keep records of certain human clinical tests and studies used to back up such claims.

Finally, the order imposes a judgment of $47,203,036 against the defendants in favor of the FTC, which will be partially suspended after they pay $500,000. If the defendants are later found to have misrepresented their financial condition to the FTC, the total amount of the judgment will become due.

The Commission vote authorizing the staff to file the complaint and stipulated final order was 2-0. The FTC filed the complaint and proposed order in the U.S. District Court for the Southern District of Florida.

NOTE: The Commission files a complaint when it has “reason to believe” that the law has been or is being violated and it appears to the Commission that a proceeding is in the public interest. Stipulated final injunctions/orders have the force of law when approved and signed by the District Court judge.

The Federal Trade Commission works to promote competition, and protect and educate consumers. You can learn more about consumer topics and file a consumer complaint online or by calling 1-877-FTC-HELP (382-4357). Like the FTC on Facebook (link is external), follow us on Twitter (link is external), read our blogs and subscribe to press releases for the latest FTC news and resources.
Contact Information

CONTACT FOR CONSUMERS:
Consumer Response Center
877-382-4357

CONTACT FOR NEWS MEDIA:
Mitchell J. Katz (link sends e-mail)
Office of Public Affairs
202-326-2161

STAFF CONTACT:
Michael J. Davis
Bureau of Consumer Protection
202-326-2458



(2)
(0)




Innovation Pharmaceuticals Inc (IPIX) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us